Kawasaki‑like Syndrome (MIS‑C): A Complete Guide

What is Kawasaki‑like Syndrome (MIS‑C)?

Multisystem Inflammatory Syndrome in Children (MIS‑C) is a rare but serious condition that appears 2–6 weeks after infection with SARS‑CoV‑2, the virus that causes COVID‑19. Because the clinical picture—fever, rash, conjunctival injection, swollen hands/feet, and heart involvement—mirrors classic Kawasaki disease, clinicians often refer to it as Kawasaki‑like syndrome. Unlike classic Kawasaki disease, which primarily affects children under five, MIS‑C can occur in older children and adolescents and frequently involves more profound shock and cardiac dysfunction.¹

MIS‑C is an immune‑mediated hyperinflammatory response rather than a direct viral attack. The body’s immune system becomes over‑active, releasing large quantities of cytokines that damage blood vessels, the heart, lungs, kidneys, brain, and gastrointestinal tract. Prompt recognition and treatment are essential to prevent long‑term organ damage.

Common Causes

While the exact trigger is still being researched, MIS‑C follows a pattern of recent SARS‑CoV‑2 exposure. The following conditions or situations are most often associated with its development:

• Recent COVID‑19 infection (confirmed by PCR or antigen test)
• Asymptomatic or mildly symptomatic SARS‑CoV‑2 infection detected only by antibody testing
• Post‑vaccination inflammatory response (extremely rare; usually linked to COVID‑19 infection rather than the vaccine)
• Genetic predisposition to hyperinflammatory responses (e.g., certain HLA types)
• Concurrent viral infections (e.g., Epstein‑Barr, adenovirus) that may amplify immune activation
• Underlying autoimmune diseases such as systemic lupus erythematosus
• Severe obesity or metabolic syndrome, which can intensify inflammatory pathways
• Previous Kawasaki disease or a family history of vasculitis
• Environmental triggers that increase cytokine release (e.g., high‑dose vitamin D intoxication—rare)
• Use of certain immune‑modulating medications that may mask early signs

Associated Symptoms

MIS‑C is called “multisystem” because it often involves several organ systems at once. The most common constellation of symptoms includes:

• Fever lasting ≥ 24 hours and frequently > 38.5 °C (101.3 °F)
• Rash—maculopapular, erythematous, or “strawberry tongue”
• Conjunctival injection (red eyes without discharge)
• Swollen, red hands and feet often with desquamation (peeling) after 1–2 weeks
• Gastrointestinal complaints—abdominal pain, vomiting, or diarrhea
• Cardiac involvement—myocarditis, reduced ejection fraction, coronary artery dilation or aneurysm, arrhythmias
• Shock or hypotension requiring fluid resuscitation or vasoactive meds
• Neurologic signs—headache, confusion, seizures (less common)
• Elevated inflammatory markers—CRP, ESR, ferritin, D‑dimer, pro‑BNP
• Laboratory evidence of recent SARS‑CoV‑2 infection (positive PCR, antigen, or serology)

When to See a Doctor

Because MIS‑C can deteriorate quickly, seek medical attention promptly if your child:

• Has a fever lasting more than 24 hours that does not respond to usual antipyretics.
• Develops a rash combined with red eyes, swollen lips, or a “strawberry” tongue.
• Shows signs of abdominal pain, persistent vomiting, or diarrhea, especially if accompanied by a fever.
• Appears unusually tired, dizzy, or light‑headed; or has a rapid heartbeat.
• Experiences swelling of the hands/feet or peeling skin on the fingertips/toes.
• Shows any signs of shock—pale, clammy skin, low blood pressure, or decreased urine output.

If you are unsure, call your pediatrician or an urgent‑care line; early evaluation can save lives.

Diagnosis

Diagnosing MIS‑C requires a systematic approach that combines clinical criteria, laboratory testing, and imaging. The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) provide overlapping case definitions; most clinicians use the CDC criteria:

1. Fever ≥ 38.0 °C (100.4 °F) for ≥ 24 hours.
2. Laboratory evidence of inflammation (elevated CRP, ESR, ferritin, pro‑calcitonin, D‑dimer, etc.).
3. Multisystem (≥ 2) organ involvement—cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurologic.
4. Temporal association with SARS‑CoV‑2 infection (positive PCR, antigen, or antibody test) or known exposure within the past 4 weeks.
5. Exclusion of alternative diagnoses (bacterial sepsis, toxic shock syndrome, etc.).

Key diagnostic tools include:

• Blood tests: CBC, CRP, ESR, ferritin, D‑dimer, pro‑BNP, troponin, liver enzymes, electrolytes, blood cultures.
• SARS‑CoV‑2 testing: RT‑PCR from nasopharyngeal swab, rapid antigen, and serology for IgG antibodies.
• Echocardiogram: Evaluates ventricular function, coronary artery size, and pericardial effusion.
• Chest X‑ray or CT: Looks for pulmonary infiltrates or pleural effusions.
• Abdominal ultrasound (if severe abdominal pain): Detects ileitis, ascites, or mesenteric lymphadenopathy.
• Electrocardiogram (ECG): Screens for arrhythmias or conduction delays.

Treatment Options

Management of MIS‑C is multidisciplinary, typically performed in a pediatric intensive‑care unit (PICU). The goals are to halt the inflammatory cascade, support organ function, and prevent long‑term sequelae.

Hospital‑Based Medical Interventions

• Intravenous Immunoglobulin (IVIG) – 2 g/kg given over 8–12 hours is first‑line; reduces fever and coronary artery inflammation in > 80 % of cases.²
• Aspirin – High‑dose (30–50 mg/kg/day) while febrile, followed by low‑dose (3–5 mg/kg/day) for antiplatelet effect once afebrile.
• Corticosteroids – Methylprednisolone 1–2 mg/kg/day (or pulse dosing) added for refractory disease or severe cardiac involvement.
• Biologic agents – Infliximab, anakinra (IL‑1 receptor antagonist), or tocilizumab (IL‑6 blocker) for IVIG‑resistant cases.
• Vasoactive medications – Epinephrine, norepinephrine, or dopamine for shock unresponsive to fluids.
• Anticoagulation – Low‑molecular‑weight heparin or enoxaparin when D‑dimer is markedly elevated or if coronary aneurysms develop.
• Respiratory support – Supplemental oxygen, CPAP, or mechanical ventilation for severe pulmonary involvement.

Supportive & Home Care After Discharge

• Complete the prescribed aspirin course (usually 4–6 weeks) and follow up with cardiology.
• Gradual return to activity; avoid high‑intensity sport for at least 4–6 weeks or until cardiac clearance.
• Maintain adequate hydration and a balanced diet to support recovery.
• Monitor temperature and watch for recurrence of fever, rash, or new chest pain.
• Schedule follow‑up labs (CRP, ESR, cardiac markers) as directed—typically at 1‑ and 2‑week intervals.

Prevention Tips

Because MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on preventing COVID‑19 itself:

• Vaccination – Keeping children up‑to‑date with age‑appropriate COVID‑19 vaccines dramatically reduces infection risk and severity.³
• Masking and ventilation in indoor settings during community surges.
• Hand hygiene – Wash hands with soap for at least 20 seconds or use an alcohol‑based sanitizer.
• Avoid close contact with anyone known to be infected.
• Early testing of symptomatic children or those with known exposure; isolate until results are known.
• Prompt treatment of acute COVID‑19 – Early antiviral therapy (e.g., Paxlovid for eligible adolescents) may reduce viral load and subsequent inflammatory sequelae.

Emergency Warning Signs

Key Take‑aways

MIS‑C is a rare but potentially life‑threatening complication of COVID‑19 that mimics Kawasaki disease. Early recognition—high fever plus rash, red eyes, gastrointestinal distress, and evidence of heart involvement—paired with prompt laboratory testing is essential. Treatment with IVIG, aspirin, and sometimes steroids or biologics dramatically improves outcomes, but close cardiac follow‑up is mandatory. Vaccination and standard infection‑control measures remain the best tools to prevent the syndrome. Always err on the side of caution: if you suspect MIS‑C, seek medical care without delay.

References:

1. Mayo Clinic. “Multisystem Inflammatory Syndrome in Children (MIS‑C).” Accessed March 2024.
2. CDC. “Clinical Care Guidance for MIS‑C.” Updated February 2024.
3. World Health Organization. “COVID‑19 Vaccines and Children.” WHO Technical Brief, 2023.
4. Cleveland Clinic. “Kawasaki Disease vs. MIS‑C.” Patient Education, 2023.
5. Feldstein LR et al. “Multisystem Inflammatory Syndrome in US Children and Adolescents.” *NEJM*, 2020;383:334‑346.